Home › Therapeutic areas › Other central nervous system agents
Japan market screening · Therapeutic class
その他の中枢神経系用薬 · Japan Standard Commodity Classification
39 molecules in this class are marketed in Japan across 484 products. 34 of those products are not shipping normally today — 7.0% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Donepezil Hydrochlorideドネペジル塩酸塩 | 115 | 21 | 12 | |
| Memantine Hydrochlorideメマンチン塩酸塩 | 95 | 21 | 8 | |
| Pregabalinプレガバリン | 85 | 23 | 4 | |
| Rivastigmineリバスチグミン | 50 | 12 | — | |
| Galantamine Hydrobromideガランタミン臭化水素酸塩 | 31 | 9 | 5 | |
| Edaravoneエダラボン | 13 | 8 | 2 | |
| Tiapride Hydrochlorideチアプリド塩酸塩 | 12 | 5 | — | |
| Taltirelin Hydrateタルチレリン水和物 | 9 | 5 | 1 | |
| Mirogabalin Besilateミロガバリンベシル酸塩 | 8 | 1 | — | |
| Nalfurafine Hydrochlorideナルフラフィン塩酸塩 | 8 | 7 | 2 | |
| Ramelteonラメルテオン | 7 | 7 | — | |
| Atogepant Hydrateアトゲパント水和物 | 3 | 1 | — | |
| Lemborexantレンボレキサント | 3 | 1 | — | |
| Melatoninメラトニン | 3 | 1 | — | |
| Nusinersen Sodiumヌシネルセンナトリウム | 3 | 1 | — | |
| Riluzoleリルゾール | 3 | 3 | — | |
| Suvorexantスボレキサント | 3 | 1 | — | |
| Vornorexant Hydrateボルノレキサント水和物 | 3 | 1 | — | |
| Daridorexant Hydrochlorideダリドレキサント塩酸塩 | 2 | 1 | — | |
| Dimethyl Fumarateフマル酸ジメチル | 2 | 1 | — | |
| Donepezilドネペジル | 2 | 1 | — | |
| Fremanezumab (Genetical Recombination)フレマネズマブ（遺伝子組換え） | 2 | 1 | — | |
| Galcanezumab (Genetical Recombination)ガルカネズマブ（遺伝子組換え） | 2 | 1 | — | |
| Lasmiditan Succinateラスミジタンコハク酸塩 | 2 | 1 | — | |
| Lecanemab (Genetical Recombination)レカネマブ（遺伝子組換え） | 2 | 1 | — | |
| Risdiplamリスジプラム | 2 | 1 | — | |
| Valbenazine Tosilateバルベナジントシル酸塩 | 2 | 1 | — | |
| Acamprosate Calciumアカンプロサートカルシウム | 1 | 1 | — | |
| Donanemab (Genetical Recombination)ドナネマブ（遺伝子組換え） | 1 | 1 | — | |
| Erenumab (Genetical Recombination)エレヌマブ（遺伝子組換え） | 1 | 1 | — | |
| Gabapentin Enacarbilガバペンチン エナカルビル | 1 | 1 | — | |
| Mazindolマジンドール | 1 | 1 | — | |
| Nalmefene Hydrochloride Hydrateナルメフェン塩酸塩水和物 | 1 | 1 | — | |
| Natalizumab (Genetical Recombination)ナタリズマブ（遺伝子組換え） | 1 | 1 | — | |
| Ofatumumab (Genetical Recombination)オファツムマブ（遺伝子組換え） | 1 | 1 | — | |
| Piracetamピラセタム | 1 | 1 | — | |
| Rimegepant Sulfate Hydrateリメゲパント硫酸塩水和物 | 1 | 1 | — | |
| Tetrabenazineテトラベナジン | 1 | 1 | — | |
| Tofersenトフェルセン | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).